Innovaderm’s Leading Expertise in Dermatology is Featured at LEO Pharma’s DELTA Program Late-Breaking Session at EADV Congress in Amsterdam, The Netherlands

Innovaderm’s leading expertise in advancing dermatology is featured at the European Academy of Dermatology and Venereology (EADV) late-breaking session on September 27^th in Amsterdam.

The abstract “Treatment response of delgocitinib cream according to CHE subtypes in adults with moderate to severe Chronic Hand Eczema (CHE): results from the Phase 3 DELTA 1, DELTA 2, and DELTA 3 trials” was authored by our founder and CEO, Dr. Robert Bissonnette, alongside Sibylle Schliemann, Melinda Gooderham, Richard B. Warren, Marie Louise Schuttelaar, Marie-Noëlle Crépy, Luca Stingeni, Jonathan I. Silverberg, Keith Baranowski, Marie Louise Oesterdal, Ursula Plohberger, Laura Soerensen and Tove Agner.

The results of these LEO Pharma-sponsored phase III trials are marking a very important milestone for this CHE study program.

Innovaderm’s clinical site was also one of the main active centers in DELTA 1 and DELTA 3 trials.

Innovaderm takes pride in its role as a substantial contributor to dermatology clinical initiatives, contributing to positive changes in the lives of patients living with life-altering skin diseases.

___

L’expertise d’Innovaderm dans l’avancement de la dermatologie est mise de l’avant lors d’une présentation de l’European Academy of Dermatology and Venereology (EADV), le 27 septembre à Amsterdam.

La présentation « Treatment response of delgocitinib cream according to CHE subtypes in adults with moderate to severe Chronic Hand Eczema (CHE): results from the Phase 3 DELTA 1, DELTA 2, and DELTA 3 trials » est présentée par notre fondateur et PDG, Dr Robert Bissonnette, aux côtés de Sibylle Schliemann, Melinda Gooderham, Richard B Warren, Marie Louise Schuttelaar, Marie-Noëlle Crépy, Luca Stingeni, Jonathan I. Silverberg, Keith Baranowski, Marie Louise Oesterdal, Ursula Plohberger, Laura Soerensen et Tove Agner.

Le site clinique d’Innovaderm a également été l’un des principaux centres actifs des études DELTA 1 et DELTA 3.

Innovaderm est fière de contribuer de manière significative à d’importants projets cliniques et de faire la différence dans la vie des patients atteints de maladies de la peau.

Newsletter